KWKerrie Woods

Kerrie Woods

*This is an algorithmically generated author record based on publicly available information.

Kerrie Woods has a total of 172 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hepatitis B Virus ( HBV ) Treatment Eligibility in the UK : Retrospective Longitudinal Cohort Data to Explore the Impact of Changes in Clinical Guidelines

    by Cori Campbell, Tingyan Wang, Alexander J. Stockdale, Stacy Todd, Jakub Jaworski, Ben Glampson, Dimitri Papadimitriou, Erik Mayer, Hizni Salih, Gail Roadknight, et al.

    Nucleos/tide analogue (NA) drugs are used for long‐term treatment of chronic hepatitis B virus (HBV) infection, with treatment eligibility criteria changing rapidly amidst globally evolving clinical guidelines. We aimed to quantify the prescription of NA drugs to date, and to undertake a preliminary assessment of the impact of relaxing treatment eligibility thresholds, leveraging a unique large real‐world secondary care dataset. We assimilated longitudinal clinical data, collected between February 1997 and April 2023 from adults with chronic HBV infection from six centres in England through the UK NIHR Health Informatics Collaborative (HIC) Viral Hepatitis and Liver Disease theme. We describe factors currently associated with the receipt of NA treatment and determine the proportion of the population who would become treatment eligible as thresholds change. Across 7558 adults with a mean follow‐up of 4.0 years (SD 3.9), NA treatment was prescribed in 2014/7558 (26.6%), and as expected according to guidelines at the time, was associated with HBV e‐antigen (HBeAg) positivity and alanine transferase (ALT) above the upper limit of normal (> ULN). Treatment was more likely in males, older adults, in Asian and Other ethnicities (compared to White), and less likely in socioeconomically deprived individuals. The proportion of treatment‐eligible individuals was 32.3% based on 2 records of ALT > ULN over 6–12 months, 41.7% based on ALT > ULN and viral load (VL) > 2000 IU/mL, and 95.1% based on detectable VL and either ALT > ULN or age > 30 years. Evolving clinical guidelines will lead to substantial increases in the proportion of individuals living with HBV who are eligible for treatment, underlining the need for services to adapt rapidly to the changing clinical environment.


  • Open Access

    Hepatitis B Virus (HBV) treatment eligibility in the UK: retrospective longitudinal cohort data to explore the impact of changes in clinical guidelines

    by Cori Campbell, Tingyan Wang, Alexander J Stockdale, Stacy Todd, Jakub Jaworski, Ben Glampson, Dimitri Papadimitriou, Erik Mayer, Hizni Salih, Gail Roadknight, et al.

    Objective: Nucleos/tide analogue (NA) drugs are used for the long-term treatment of chronic hepatitis B virus (HBV) infection. In a landscape of changing clinical recommendations, we set out to quantify the prescription of NA drugs to date, and to determine the impact of relaxing treatment eligibility criteria in a unique large real-world dataset. Design: We assimilated longitudinal data from adults with chronic HBV infection from six centres in England through the UK National Institute for Health Research (NIHR) Health Informatics Collaborative (HIC) viral hepatitis framework. We describe factors currently associated with receipt of NA treatment, and determine the proportion of the population who would become treatment eligible as thresholds change. Results: We reviewed data for 7558 adults, with mean follow up of 4.0 years (SD 3.9 years). NA treatment was prescribed in 2014/7558 (26.6%), and in line with existing guidelines was associated with HBeAg positivity and ALT above the upper limit of normal (ULN). Treatment was significantly more likely in males, older adults, in Asian and Other ethnicities (as compared to White), and significantly less likely in socioeconomically deprived individuals. The proportion of individuals who were treatment eligible was 32.3% based on 2 records of ALT>ULN over 6-12 months; 41.7% based on ALT>ULN and VL > 2000 IU/ml; and 95.1% based on detectable VL and either ALT>ULN or age>30 years. Conclusion: We quantify the proportion of the population living with HBV who may become treatment eligible as guidelines change, providing insights to support the implementation of clinical services. KEY MESSAGES (3-5 sentences required by Gut ): • What is already known on this topic: To date, only a minority of adults living with chronic hepatitis B (CHB) infection have been eligible for treatment with nucleos/tide analogue (NA) therapy. However, worldwide guidelines are changing, with recommendations for treatment of an increasing proportion of the population. There is a need for evidence to inform the design of services to meet the needs of people living with CHB as more of the population becomes treatment eligible. • What this study adds: We have determined the proportion of the UK population of people living with HBV infection who are currently treated, and determined the increasing proportion who would become eligible as treatment criteria change, with this proportion reaching 95% based on the least stringent treatment thresholds. • How this study might affect research, practice or policy: Our study provides crucial real-world evidence that can inform planning of service delivery and resource allocation for people living with HBV, in a landscape of changing clinical guidelines.


  • Open Access

    Classification of virologic trajectories during nucleos/tide analogue treatment of hepatitis B virus (HBV) infection

    by Tingyan Wang, Cori Campbell, Alexander J Stockdale, Stacy Todd, Karl McIntyre, Andrew Frankland, Jakub Jaworski, Ben Glampson, Dimitri Papadimitriou, Luca Mercuri, et al.

    Background & Aims: The dynamics of HBV viral load (VL) in patients with chronic hepatitis B (CHB) on nucleos/tide analogue (NA) treatment and its relationship with liver disease are poorly understood. We aimed to study longitudinal VL patterns and their associations with CHB clinical outcomes. Methods: Utilising large scale, routinely collected electronic health records from six centres in England, collated by the National Institute for Health and Care Research Health Informatics Collaborative (NIHR HIC), we applied latent class mixed models to investigate VL trajectory patterns in adults receiving NA treatment. We assessed associations of VL trajectory with alanine transaminase (ALT), and with liver fibrosis/cirrhosis. Results: We retrieved data from 1885 adults on NA treatment (median follow-up 6.2 years, interquartile range (IQR) 3.7-9.3 years), with 21,691 VL measurements (median 10 per patient, IQR 5-17). Five VL classes were identified from the derivation cohort (n=1367, discrimination: 0.93, entropy: 0.90): class 1 ‘long term suppression’ (n=827, 60.5%), class 2 ‘timely virological suppression’ (n=254, 18.6%), class 3 ‘persistent moderate viraemia’ (n=140, 10.2%), class 4 ‘persistent high-level viraemia’ (n=44, 3.2%), and class 5 ‘slow virological suppression’ (n=102, 7.5%). The model demonstrated a discrimination of 0.93 and entropy of 0.88 for the validation cohort (n=518). ALT decreased variably over time in VL-suppressed groups (classes 1, 2, 5; all p<0.001), but did not significantly improve in those with persistent viraemia (classes 3, 4). Patients in class 5 had 2-fold increased hazards of fibrosis/cirrhosis compared to class 1 (adjusted hazard ratio, 2.00; 95% CI, 1.33-3.02). Conclusions: Heterogeneity exists in virological response to NA therapy in CHB patients, with over 20% showing potentially suboptimal responses. Slow virological suppression is associated with liver disease progression.


  • Open Access

    The association between troponin level and mortality in patients admitted to hospital with acute stroke (NIHR Health Informatics Collaborative TROP-STROKE study)

    by A Kaura, A J Roddick, N A Samuel, A Mulla, B Glampson, J Davies, K Woods, R Kharbanda, R S Patel, A M Shah, et al.

    Introduction: Acute stroke accounts for significant morbidity and mortality globally. The role of troponin for risk stratification in stroke is unclear. Purpose: The aims of this study were to assess the relationship between peak troponin and mortality in patients with ischaemic stroke, haemorrhagic stroke, or subarachnoid haemorrhage and to compare this with the predictive value of first troponin or dynamic troponin change. Methods: A retrospective cohort study was carried out using the National Institute for Health Research Health Informatics Collaborative Cardiovascular dataset of all consecutive patients who had a troponin measured at five hospitals between 2010 and 2017. Patients with at least one troponin measurement and a primary diagnosis of ischaemic stroke, haemorrhagic stroke or subarachnoid haemorrhage during a hospital admission were included. The main exposure variables were first and peak troponin, and dynamic troponin change, and the main outcome was all-cause mortality. Results were analysed using multivariable adjusted restricted cubic spline Cox regression. Survival analyses were adjusted for troponin assay, assay sensitivity (standard or highly sensitive), number of troponin measurements, age, sex, C-reactive protein level, white blood cell count, platelet count, haemoglobin, estimated glomerular filtration rate, angiography during admission, acute coronary syndrome during admission, and cardiovascular history (history of diabetes mellitus, myocardial infarction, heart failure, hypertension, stroke or atrial fibrillation). Receiver Operator Characteristic (ROC) curves were used to assess the predictive value of each exposure variable. Results: 4,712 patients were included in the analysis (ischaemic stroke: 3,346; haemorrhagic stroke: 718; subarachnoid haemorrhage: 648). Peak troponin was above the upper limit of normal in 47.4% of ischaemic stroke patients, 52.8% of haemorrhagic stroke patients, and 57.1% of subarachnoid haemorrhage patients. Patients with elevated peak troponin were older and had more cardiovascular risk factors. A direct positive relationship was seen between peak troponin level and mortality hazard ratio in all three stroke subtypes (Figure 1). This relationship was consistent when considering dynamic troponin fold change for ischaemic or haemorrhagic stroke. For all three stroke subtypes, there was no added predictive value of peak troponin or dynamic troponin change over first troponin in predicting mortality (Figure 2). Conclusions: A positive peak troponin was associated with increased mortality in patients presenting with ischaemic stroke, haemorrhagic stroke, or subarachnoid haemorrhage. Overall, serial troponin measurements may not improve mortality prediction beyond a single measurement. These findings may have implications for risk stratification of patients with acute stroke syndromes. Funding Acknowledgement: Type of funding sources: Public grant(s) – National budget only. Main funding source(s): NIHR Imperial Biomedical Research Centre, as part of the NIHR Health Informatics Collaborative, and 2) British Heart Foundation

  • Open Access

    Identifying Hepatocellular Carcinoma from imaging reports using natural language processing to facilitate data extraction from electronic patient records

    by Tingyan Wang, Ben Glampson, Luca Mercuri, Dimitri Papadimitriou, Christopher R Jones, David A Smith, Hizni Salih, Cori Campbell, Oliver Freeman, Steve Harris, et al.

    Background The National Institute for Health Research Health Informatics Collaborative (NIHR HIC) viral hepatitis theme is working to overcome governance and data challenges to collate routine clinical data from electronic patients records from multiple UK hospital sites for translational research. The development of hepatocellular carcinoma (HCC) is a critical outcome for patients with viral hepatitis with the drivers of cancer transformation poorly understood. Objective This study aims to develop a natural language processing (NLP) algorithm for automatic HCC identification from imaging reports to facilitate studies into HCC. Methods 1140 imaging reports were retrieved from the NIHR HIC viral hepatitis research database v1.0. These reports were from two sites, one used for method development (site 1) and the other for validation (site 2). Reports were initially manually annotated as binary classes (HCC vs. non-HCC). We designed inference rules for recognising HCC presence, wherein medical terms for eligibility criteria of HCC were determined by domain experts. A rule-based NLP algorithm with five submodules (regular expressions of medical terms, terms recognition, negation detection, sentence tagging, and report label generation) was developed and iteratively tuned. Results Our rule-based algorithm achieves an accuracy of 99.85% (sensitivity: 90%, specificity: 100%) for identifying HCC on the development set and 99.59% (sensitivity: 100%, specificity: 99.58%) on the validation set. This method outperforms several off-the-shelf models on HCC identification including “machine learning based” and “deep learning based” text classifiers in achieving significantly higher sensitivity. Conclusion Our rule-based NLP method gives high sensitivity and high specificity for HCC identification, even from imbalanced datasets with a small number positive cases, and can be used to rapidly screen imaging reports, at large-scale to facilitate epidemiological and clinical studies into HCC. Problem Establishing a cohort of hepatocellular carcinoma (HCC) from imaging reports via manual review requires advanced clinical knowledge and is costly, time consuming, impractical when performed on a large scale. What is Already Known Although some studies have applied natural language processing (NLP) techniques to facilitate identifying HCC information from narrative medical data, the proposed methods based on a pre-selection by diagnosis codes, or subject to certain standard templates, have limitations in application. What This Paper Adds We have developed a hierarchical rule-based NLP method for automatic identification of HCC that uses diagnostic concepts and tumour feature representations that suggest an HCC diagnosis to form reference rules, accounts for differing linguistic styles within reports, and embeds a data pre-processing module that can be configured and customised for different reporting formats. In doing so we have overcome major challenges including the analysis of imbalanced data (inherent in clinical records) and lack of existing unified reporting standards.

  • Open Access

    Prognostic Significance of Ventricular Arrhythmias in 13 444 Patients With Acute Coronary Syndrome: A Retrospective Cohort Study Based on Routine Clinical Data (NIHR Health Informatics Collaborative VA‐ACS Study)

    by Arunashis Sau, Amit Kaura, Amar Ahmed, Kiran H. K. Patel, Xinyang Li, Abdulrahim Mulla, Benjamin Glampson, Vasileios Panoulas, Jim Davies, Kerrie Woods, et al.

    Background: A minority of acute coronary syndrome (ACS) cases are associated with ventricular arrhythmias (VA) and/or cardiac arrest (CA). We investigated the effect of VA/CA at the time of ACS on long‐term outcomes. Methods and Results: We analyzed routine clinical data from 5 National Health Service trusts in the United Kingdom, collected between 2010 and 2017 by the National Institute for Health Research Health Informatics Collaborative. A total of 13 444 patients with ACS, 376 (2.8%) of whom had concurrent VA, survived to hospital discharge and were followed up for a median of 3.42 years. Patients with VA or CA at index presentation had significantly increased risks of subsequent VA during follow‐up (VA group: adjusted hazard ratio [HR], 4.15 [95% CI, 2.42–7.09]; CA group: adjusted HR, 2.60 [95% CI, 1.23–5.48]). Patients who suffered a CA in the context of ACS and survived to discharge also had a 36% increase in long‐term mortality (adjusted HR, 1.36 [95% CI, 1.04–1.78]), although the concurrent diagnosis of VA alone during ACS did not affect all‐cause mortality (adjusted HR, 1.03 [95% CI, 0.80–1.33]). Conclusions: Patients who develop VA or CA during ACS who survive to discharge have increased risks of subsequent VA, whereas those who have CA during ACS also have an increase in long‐term mortality. These individuals may represent a subgroup at greater risk of subsequent arrhythmic events as a result of intrinsically lower thresholds for developing VA.


  • Open Access

    Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: A cohort study

    by Amit Kaura, Adam Hartley, Vasileios Panoulas, Ben Glampson, Anoop S. V. Shah, Jim Davies, Abdulrahim Mulla, Kerrie Woods, Joe Omigie, Mark R. Thursz, et al.

    Background: There is limited evidence on the use of high-sensitivity C-reactive protein (hsCRP) as a biomarker for selecting patients for advanced cardiovascular (CV) therapies in the modern era. The prognostic value of mildly elevated hsCRP beyond troponin in a large real-world cohort of unselected patients presenting with suspected acute coronary syndrome (ACS) is unknown. We evaluated whether a mildly elevated hsCRP (up to 15 mg/L) was associated with mortality risk, beyond troponin level, in patients with suspected ACS. Methods and findings: We conducted a retrospective cohort study based on the National Institute for Health Research Health Informatics Collaborative data of 257,948 patients with suspected ACS who had a troponin measured at 5 cardiac centres in the United Kingdom between 2010 and 2017. Patients were divided into 4 hsCRP groups (<2, 2 to 4.9, 5 to 9.9, and 10 to 15 mg/L). The main outcome measure was mortality within 3 years of index presentation. The association between hsCRP levels and all-cause mortality was assessed using multivariable Cox regression analysis adjusted for age, sex, haemoglobin, white cell count (WCC), platelet count, creatinine, and troponin. Following the exclusion criteria, there were 102,337 patients included in the analysis (hsCRP 15 mg/L makes it unlikely that sepsis was a major contributor. Conclusions: These multicentre, real-world data from a large cohort of patients with suspected ACS suggest that mildly elevated hsCRP (up to 15 mg/L) may be a clinically meaningful prognostic marker beyond troponin and point to its potential utility in selecting patients for novel treatments targeting inflammation. Trial registration: ClinicalTrials.gov - NCT03507309


  • Abstract 14169: Implications of Elevated Troponin on Time-to-Surgery in Non-ST Elevation Myocardial Infarction (NIHR Health Informatics Collaborative: Trop-CABG Study)

    by Shubhra Sinha, Umberto Benedetto, Abdulrahim Mulla, Ben Glampson, Vasileios F. Panoulas, Sanjay Gautama, Jim Davies, Dimitri Papadimitriou, Kerrie Woods, Paul Elliott, et al.

    Background: The optimal timing of coronary artery bypass grafting(CABG) in patients with non-ST elevation myocardial infarction (NSTEMI) and the utility of pre-operative troponin levels in decision-making remains unclear. We investigated (a)the association between peak pre-operative troponin and survival post-CABG in a large cohort of NSTEMI patients and (b)the interaction between troponin and time-to-surgery. Methods: Our cohort consisted of 1746 NSTEMI patients(mean age 69±11 years, 21% female) with recorded troponins that had CABG at five United Kingdom centers between 2010 and 2017. Time-segmented Cox regression was used to investigate the interaction of peak troponin and time-to-surgery on early(within 30 days) and late(beyond 30 days) survival. Results: Average interval from peak troponin to surgery was 9±15 days, with 1466(84.0%) patients having CABG during the same admission. Sixty patients died within 30-days and another 211 died after a mean follow-up of 4±2years(30-day survival 0.97±0.004 and 5-year survival 0.83±0.01). Peak troponin was a strong predictor of early survival(adjusted P=0.002) with a significant interaction with time-to-surgery(P interaction=0.007). For peak troponin levels Conclusions: Peak troponin in NSTEMI patients undergoing CABG was a significant predictor of early mortality, strongly influenced the time-to-surgery and may prove to be a clinically useful biomarker in the management of these patients.


  • Open Access

    Cohort Profile: National Institute for Health Research Health Informatics Collaborative: Hepatitis B Virus (NIHR HIC HBV) Research Dataset

    by Tingyan Wang, David A Smith, Cori Campbell, Oliver Freeman, Zuzana Moysova, Theresa Noble, Kinga A Várnai, Steve Harris, Hizni Salih, Gail Roadknight, et al.

    Purpose The National Institute for Health Research (NIHR) Health Informatics Collaborative (HIC) was established to enable re-use of routinely collected clinical data across National Health Service (NHS) Trusts in the United Kingdom to support translational research. Viral hepatitis is one of the first five exemplar themes and hepatitis B virus (HBV) is the current focus of the theme. The NIHR HIC HBV dataset, derived from the central data repository of NIHR HIC viral hepatitis theme, aims to describe and characterise HBV infection in secondary care in the United Kingdom, and provides a resource for translational research. Participants The dataset comprises >5000 individuals (99% adults aged ≥18, 1% children aged Findings to date Data on demographics, laboratory tests, antiviral treatment, elastography scores, imaging/biopsy reports, death information, and potential risk factors for liver disease have been collected. Data are captured by electronic patient record (EPR) systems, and records are updated prospectively as new results are added. This cohort profile describes the dataset in its current form. Among the adults, 55% are male, and the median age at index date (defined as the first recorded positive hepatitis B virus surface antigen (HBsAg) or HBV DNA in EPR systems) was 40 years (interquartile range [IQR]: 32-50). For those individuals with ethnicity reported, 30% were Asian, 24% were Black, 30% were White, and the remaining 16% were mixed or other ethnic groups. Currently, the median follow-up duration of the adult patients in this dataset was 5.0 (IQR: 2.7-7.5) years, with 9.3 (95% CI: 8.2-10.5) deaths per 1,000 person-years. We have already conducted several analyses using subsets of this dataset including an evaluation of distribution and trajectories of HBsAg and HBV viral load in CHB, reviewing the use of antiviral treatment, quantifying the burden of liver disease in the untreated population, and studying the use of laboratory biomarkers to improve stratification and surveillance. Future plans Longitudinal data collection is continuing, with the sample growing in size, more parameters being collected, average follow-up increasing, and more NHS Trusts participating. This dataset offers important opportunities for epidemiological studies and biomedical informatics research, as well as characterising an HBV population for clinical trials through external collaborations with industry.


  • Open Access

    Longitudinal Analysis of the Utility of Liver Biochemistry as Prognostic Markers in Hospitalized Patients With Corona Virus Disease 2019

    by Tingyan Wang, David A. Smith, Cori Campbell, Steve Harris, Hizni Salih, Kinga A. Várnai, Kerrie Woods, Theresa Noble, Oliver Freeman, Zuzana Moysova, et al.

    The association of liver biochemistry with clinical outcomes of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection is currently unclear, and the utility of longitudinally measured liver biochemistry as prognostic markers for mortality is unknown. We aimed to determine whether abnormal liver biochemistry, assessed at baseline and at repeat measures over time, was associated with death in hospitalized patients with COVID‐19 compared to those without COVID‐19, in a United Kingdom population. We extracted routinely collected clinical data from a large teaching hospital in the United Kingdom, matching 585 hospitalized patients who were SARS‐CoV‐2 real‐time reverse transcription‐polymerase chain reaction (RT‐PCR) positive to 1,165 hospitalized patients who were RT‐PCR negative for age, sex, ethnicity, and preexisting comorbidities. A total of 26.8% (157/585) of patients with COVID‐19 died compared to 11.9% (139/1,165) in the group without COVID‐19 (P < 0.001). At presentation, a significantly higher proportion of the group with COVID‐19 had elevated alanine aminotransferase (20.7% vs. 14.6%, P = 0.004) and hypoalbuminemia (58.7% vs. 35.0%, P < 0.001) compared to the group without COVID‐19. Within the group with COVID‐19, those with hypoalbuminemia at presentation had 1.83‐fold increased hazards of death compared to those with normal albumin (adjusted hazard ratio [HR], 1.83; 95% confidence interval [CI], 1.25‐2.67), while the hazard of death was ~4‐fold higher in those aged ≥75 years (adjusted HR, 3.96; 95% CI, 2.59‐6.04) and ~3‐fold higher in those with preexisting liver disease (adjusted HR, 3.37; 95% CI, 1.58‐7.16). In the group with COVID‐19, alkaline phosphatase (ALP) increased (R = 0.192, P < 0.0001) and albumin declined (R = −0.123, P = 0.0004) over time in patients who died. Conclusion: In this United Kingdom population, liver biochemistry is commonly deranged in patients with COVID‐19. Baseline hypoalbuminemia and rising ALP over time could be prognostic markers for death, but investigation of larger cohorts is required to develop a better understanding of the relationship between liver biochemistry and disease outcome.